EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

PLGA and Eudragit-based long-acting microspheres for Parkinson's disease management

Deepa D. Nakmode, Haripriya Koppisetti, Weranga Rajapaksha, Yunmei Song, Sanjay Garg

RSC Pharmaceutics · 2026 · 3 (4) · 1071-1085

DOI: 10.1039/d6pm00029k ↗

Kurz gefasst

Fachartikel in der Zeitschrift RSC Pharmaceutics, 2026. Verfasst von Deepa D. Nakmode und 4 weiteren Autor:innen. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A long-acting PLGA/Eudragit microsphere formulation was developed to replace frequent oral dosing for Parkinson's disease. It successfully delivered hydrophilic pramipexole, achieving sustained release for up to 18 days with excellent syringeability.

Zitieren

APA

Nakmode, D. D., Koppisetti, H., Rajapaksha, W., Song, Y., & Garg, S. (2026). PLGA and Eudragit-based long-acting microspheres for Parkinson's disease management. RSC Pharmaceutics, 3(4), 1071-1085. https://doi.org/10.1039/d6pm00029k

Vancouver

Nakmode DD, Koppisetti H, Rajapaksha W, Song Y, Garg S. PLGA and Eudragit-based long-acting microspheres for Parkinson's disease management. RSC Pharmaceutics. 2026;3(4):1071-1085. doi:10.1039/d6pm00029k

BibTeX
@article{Nakmode2026,
  author = {Nakmode, Deepa D. and Koppisetti, Haripriya and Rajapaksha, Weranga and Song, Yunmei and Garg, Sanjay},
  title = {PLGA and Eudragit-based long-acting microspheres for Parkinson's disease management},
  journal = {RSC Pharmaceutics},
  year = {2026},
  volume = {3},
  number = {4},
  pages = {1071--1085},
  doi = {10.1039/d6pm00029k}
}
Kostenlos starten →